UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma

Clinical cancer research, 2015-02, Vol.21 (3), p.553-560

2015

Volltextzugriff (PDF)

Fuzzy simulation of pharmacokinetic models: Case study of whole body physiologically based model of diazepam

Journal of pharmacokinetics and pharmacodynamics, 2004-06, Vol.31 (3), p.185-213

2004

Volltextzugriff (PDF)

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

British journal of cancer, 2018-11, Vol.119 (10), p.1208-1214

2018

Volltextzugriff (PDF)

Handling Missing Data in a Duloxetine Population Pharmacokinetic/Pharmacodynamic Model – Imputation Methods and Selection Models

Pharmaceutical research, 2014-10, Vol.31 (10), p.2829-2843

2014

Volltextzugriff (PDF)

Incorporating Correlation in Interindividual Variability for the Optimal Design of Multiresponse Pharmacokinetic Experiments

Journal of biopharmaceutical statistics, 2008-01, Vol.18 (2), p.342-358

2008

Volltextzugriff (PDF)

Incorporating measures of variability and uncertainty into the prediction of in vivo hepatic clearance from in vitro data

Drug metabolism and disposition, 2002-03, Vol.30 (3), p.276-282

2002

Volltextzugriff (PDF)

Integrated data review of the first-in-human dose (FHD) study evaluating safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor, LY2157299 monohydrate (LY)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.2016-2016

2013

Volltextzugriff (PDF)

Investigating the impact of target lesion selection on drug effect evaluation and tumour growth rate determination using tumour growth inhibition models: Example of malignant pleural mesothelioma patients treated with cisplatin alone or in combination with pemetrexed

European journal of pharmaceutical sciences, 2021-06, Vol.161, p.105781-105781, Article 105781

2021

Volltextzugriff (PDF)

Linking preclinical and clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEM

European journal of clinical pharmacology, 2007-05, Vol.63 (5), p.485-498

2007

Volltextzugriff (PDF)

Mechanism for Enhanced Absorption of a Solid Dispersion Formulation of LY2300559 Using the Artificial Stomach Duodenum Model

Molecular pharmaceutics, 2015-04, Vol.12 (4), p.1131-1140

2015

Volltextzugriff (PDF)

Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancer

British journal of clinical pharmacology, 2016-09, Vol.82 (3), p.717-727

2016

Volltextzugriff (PDF)

Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma

Liver international, 2019-08, Vol.39 (8), p.1468-1477

2019

Volltextzugriff (PDF)

Optimal design for multiresponse pharmacokinetic-pharmacodynamic models - dealing with unbalanced designs

Journal of pharmacokinetics and pharmacodynamics, 2007-06, Vol.34 (3), p.313-331

2007

Volltextzugriff (PDF)

Optimal design for multivariate response pharmacokinetic models

Journal of pharmacokinetics and pharmacodynamics, 2006-04, Vol.33 (2), p.97-124

2006

Volltextzugriff (PDF)

The oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 plus lomustine in patients with treatment-refractory malignant glioma: The first human dose study

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.2042-2042

2012

Volltextzugriff (PDF)

Pharmacokinetic modelling of interleukin‐1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage

British journal of clinical pharmacology, 2008-03, Vol.65 (3), p.317-325

2008

Volltextzugriff (PDF)

Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid heamorrhage

British journal of clinical pharmacology, 2008, Vol.65 (3), p.317-325

2008

Volltextzugriff (PDF)

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-[beta] receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer

Investigational new drugs, 2015-04, Vol.33 (2), p.357

2015

Volltextzugriff (PDF)

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer

Investigational new drugs, 2015-04, Vol.33 (2), p.357-370

2015

Volltextzugriff (PDF)

A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2017-04, Vol.79 (4), p.673-680

2017

Volltextzugriff (PDF)

A phase 1 study of anti-TGF[beta] receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2017-04, Vol.79 (4), p.673

2017

Volltextzugriff (PDF)

Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2015-12, Vol.76 (6), p.1143-1152

2015

Volltextzugriff (PDF)

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma

Investigational new drugs, 2020-10, Vol.38 (5), p.1570-1579

2020

Volltextzugriff (PDF)

Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma

Cancer medicine (Malden, MA), 2021-05, Vol.10 (9), p.3059-3067

2021

Volltextzugriff (PDF)

A phase 2 study of a novel transforming growth factor-beta (TGF-β1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepatocellular carcinoma (HCC)

Journal of clinical oncology, 2014-01, Vol.32 (3_suppl), p.LBA173-LBA173

2014

Volltextzugriff (PDF)

26 – 50 von 73

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieCancer Research

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(71)
Mit Volltextzugriff
(67)

Publikationsform

Artikel
(72)
Dissertationen
(1)

Sprache

Englisch
(73)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma

Fuzzy simulation of pharmacokinetic models: Case study of whole body physiologically based model of diazepam

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

Handling Missing Data in a Duloxetine Population Pharmacokinetic/Pharmacodynamic Model – Imputation Methods and Selection Models

Incorporating Correlation in Interindividual Variability for the Optimal Design of Multiresponse Pharmacokinetic Experiments

Incorporating measures of variability and uncertainty into the prediction of in vivo hepatic clearance from in vitro data

Integrated data review of the first-in-human dose (FHD) study evaluating safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor, LY2157299 monohydrate (LY)

Investigating the impact of target lesion selection on drug effect evaluation and tumour growth rate determination using tumour growth inhibition models: Example of malignant pleural mesothelioma patients treated with cisplatin alone or in combination with pemetrexed

Linking preclinical and clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEM

Mechanism for Enhanced Absorption of a Solid Dispersion Formulation of LY2300559 Using the Artificial Stomach Duodenum Model

Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancer

Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma

Optimal design for multiresponse pharmacokinetic-pharmacodynamic models - dealing with unbalanced designs

Optimal design for multivariate response pharmacokinetic models

The oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 plus lomustine in patients with treatment-refractory malignant glioma: The first human dose study

Pharmacokinetic modelling of interleukin‐1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage

Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid heamorrhage

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-[beta] receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer

A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

A phase 1 study of anti-TGF[beta] receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma

Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma

A phase 2 study of a novel transforming growth factor-beta (TGF-β1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepatocellular carcinoma (HCC)

Aktive Filter

Suchergebnisse filtern